Differences in immune cell population subsets in inflammatory bowel disease patients under anti-TNF treatment

被引：0
|
作者：
Notararigo, S. [1 ,2 ]
Vinuela Roldan, J. E. [3 ]
Abanades-Tercero, M. [4 ]
Dominguez-Munoz, J. E. [1 ]
Barreiro-de Acosta, M. [1 ]
机构：
[1] Univ Hosp, Gastroenterol, Santiago De Compostela, Spain
[2] Fdn Ramon Dominguez, Santiago, Spain
[3] Univ Hosp, Immunol, Santiago, Spain
[4] Hosp Virgen Salud, Gastroenterol, Toledo, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷
关键词：
D O I：
10.1093/ecco-jcc/jjy222.186
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P062
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [31] AN AUDIT OF ADHERENCE TO ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Duncan, J.
    Sastrillo, M.
    Baker, J.
    Younge, L.
    Anderson, S.
    Lindsay, J.
    Sanderson, J.
    Irving, P.
    [J]. GUT, 2011, 60
  • [32] Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy
    José Miranda-Bautista
    Celia de Gracia-Fernández
    María López-Ibáñez
    María Barrientos
    Alejandra Gallo-Moltó
    Marina González-Arias
    Casilda González-Gil
    Alicia Díaz-Redondo
    Ignacio Marín-Jiménez
    Luis Menchén
    [J]. Digestive Diseases and Sciences, 2015, 60 : 2130 - 2135
  • [33] Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy
    Carmen Guillen, M.
    Magdalena Alcover, M.
    Borruel, Natalia
    Sulleiro, Elena
    Salvador, Fernando
    Berenguer, Diana
    Herrera-de Guise, Claudia
    Rodriguez, Veronica
    Moure, Zaira
    Sanchez-Montalva, Adrian
    Molina, Israel
    Fisa, Roser
    Riera, Cristina
    [J]. HELIYON, 2020, 6 (05)
  • [34] Inflammatory bowel disease: anti-TNF strategies and beyond
    Hoffmann, JC
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 : S76 - S78
  • [35] Inflammatory bowel disease after anti-TNF drugs
    Hamilton, Louise
    Griffin, Jane
    Dahiya, Sandeep
    Somerville, Margaret
    Stodell, Malcolm
    [J]. RHEUMATOLOGY, 2008, 47 : II18 - II18
  • [36] Optimizing anti-TNF treatments in inflammatory bowel disease
    Ben-Horin, Shomron
    Kopylov, Uri
    Chowers, Yehuda
    [J]. AUTOIMMUNITY REVIEWS, 2014, 13 (01) : 24 - 30
  • [37] How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
    Culver, Emma L.
    Travis, Simon P. L.
    [J]. CURRENT DRUG TARGETS, 2010, 11 (02) : 198 - 218
  • [38] Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease
    Schultheiss, Johannes P. D.
    Mahmoud, Remi
    Louwers, Jonas M.
    van der Kaaij, Michiel T.
    van Hellemondt, Boris P.
    van Boeckel, Petra G.
    Mahmmod, Nofel
    Jharap, Bindia
    Fidder, Herma H.
    Oldenburg, Bas
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1298 - 1308
  • [39] Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy
    Sochal, Marcin
    Fichna, Jakub
    Gabryelska, Agata
    Talar-Wojnarowska, Renata
    Bialasiewicz, Piotr
    Malecka-Wojciesko, Ewa
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [40] Treatment Adherence of Anti-TNF Drugs in the Patients with Inflammatory Bowel Disease: A Scale Development Study
    Basak, Nur
    Uran, Berna Nilgun Ozgursoy
    Yuksel, Elif Saritas
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (04): : 336 - +
12345